MX2022006663A - Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. - Google Patents

Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.

Info

Publication number
MX2022006663A
MX2022006663A MX2022006663A MX2022006663A MX2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A
Authority
MX
Mexico
Prior art keywords
oxygen
containing heterocyclic
heterocyclic compound
preparation
application
Prior art date
Application number
MX2022006663A
Other languages
English (en)
Inventor
Zusheng Xu
Yangtong Lou
Tiegang Xie
Original Assignee
Shanghai Yingli Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202011077052.0A external-priority patent/CN112979664B/zh
Application filed by Shanghai Yingli Pharm Co Ltd filed Critical Shanghai Yingli Pharm Co Ltd
Publication of MX2022006663A publication Critical patent/MX2022006663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulga un compuesto heterocíclico que contiene oxígeno, un método de preparación de este y el uso de este. La presente divulgación proporciona un compuesto heterocíclico que contiene oxígeno representado por la fórmula I, una sal farmacéuticamente aceptable de este, un estereoisómero de este, un tautómero de este o un compuesto isotópico de este. Cabe esperar que el compuesto heterocíclico que contiene oxígeno pueda tratar y/o prevenir diversas enfermedades mediadas por Ras. (ver Fórmula).
MX2022006663A 2019-12-02 2020-10-21 Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. MX2022006663A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911212840 2019-12-02
CN202010368798 2020-04-29
CN202011077052.0A CN112979664B (zh) 2019-12-02 2020-10-10 一种含氧杂环化合物、其制备方法及应用
PCT/CN2020/122335 WO2021109737A1 (zh) 2019-12-02 2020-10-21 一种含氧杂环化合物、其制备方法及应用

Publications (1)

Publication Number Publication Date
MX2022006663A true MX2022006663A (es) 2022-07-05

Family

ID=76221416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006663A MX2022006663A (es) 2019-12-02 2020-10-21 Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.

Country Status (9)

Country Link
US (1) US20220315598A1 (es)
EP (1) EP4015520A4 (es)
JP (1) JP7480298B2 (es)
KR (1) KR20220136349A (es)
AU (1) AU2020395397A1 (es)
BR (1) BR112022010254A2 (es)
CA (1) CA3163218A1 (es)
MX (1) MX2022006663A (es)
WO (1) WO2021109737A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
AU2020337938A1 (en) 2019-08-29 2022-03-17 Array Biopharma Inc. KRas G12D inhibitors
AU2020356455A1 (en) 2019-09-24 2022-04-14 Mirati Therapeutics, Inc. Combination therapies
CN114867726B (zh) 2019-10-28 2023-11-28 默沙东有限责任公司 Kras g12c突变体的小分子抑制剂
CA3161278A1 (en) 2019-12-20 2021-06-24 Matthew Arnold Marx Sos1 inhibitors
KR20220152295A (ko) 2020-03-12 2022-11-15 디3 바이오(우씨) 컴퍼니 리미티드 피리미도헤테로사이클릭 화합물 및 이의 응용
US20220112204A1 (en) * 2020-10-14 2022-04-14 Accutar Biotechnology Inc. Substituted dihydropyranopyrimidine compounds as kras inhibitors
WO2022187527A1 (en) * 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Quinazoline nitrile derivatives as kras inhibitors
CN115385923A (zh) * 2021-05-24 2022-11-25 上海璎黎药业有限公司 一种含氧杂环化合物的晶型、其制备方法及应用
WO2023008462A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
WO2023205074A1 (en) * 2022-04-18 2023-10-26 Mirati Therapeutics, Inc. Processes and intermediates for synthesis of adagrasib
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064705A1 (ja) * 2008-12-05 2010-06-10 大日本住友製薬株式会社 Ｈ４受容体アンタゴニスト作用を有する新規７位置換ジヒドロピラノピリミジン誘導体
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂
CA2981530A1 (en) * 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EA201890153A1 (ru) * 2015-06-26 2018-06-29 КАДМОН КОРПОРЕЙШН, ЭлЭлСи Ингибиторы поглощения глюкозы
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
CA3024523A1 (en) * 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2020521742A (ja) * 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Ｋｒａｓの共有結合性阻害剤
UA125802C2 (uk) * 2017-11-15 2022-06-08 Міраті Терапьютікс, Інк. Інгібітори kras g12c
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
CN112218859A (zh) * 2018-04-04 2021-01-12 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
KR20220152295A (ko) * 2020-03-12 2022-11-15 디3 바이오(우씨) 컴퍼니 리미티드 피리미도헤테로사이클릭 화합물 및 이의 응용

Also Published As

Publication number Publication date
JP7480298B2 (ja) 2024-05-09
US20220315598A1 (en) 2022-10-06
EP4015520A1 (en) 2022-06-22
CA3163218A1 (en) 2021-06-10
AU2020395397A1 (en) 2022-06-09
KR20220136349A (ko) 2022-10-07
WO2021109737A1 (zh) 2021-06-10
JP2023504178A (ja) 2023-02-01
EP4015520A4 (en) 2023-08-23
BR112022010254A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
MX2022005610A (es) Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
CA2983481A1 (en) Janus kinase inhibitor
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
PH12021550713A1 (en) Medicament for the treatment of chronic cough
EP4342473A3 (en) Compounds useful in hiv therapy
PH12019501955A1 (en) Tri-cycle compound and applications thereof
MY194106A (en) Dihydroindolizinone derivative
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2021007247A (es) Derivados de rapamicina.
PH12019550154A1 (en) Azetidine derivative
MX2021012105A (es) Compuestos de pirrol.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
WO2019153007A3 (en) Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood